Terms: = Prostate cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Treatment
308 results:
1. The Predictive Role of Serum Lipid Levels, p53 and ki-67, According to Molecular Subtypes in Breast cancer: A Randomized Clinical Study.
Faur IF; Dobrescu A; Clim IA; Pasca P; Prodan-Barbulescu C; Tarta C; Neamtu AA; Brebu D; Neamtu C; Rosu M; Duta C; Clim A; Lazar G; Totolici B
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612725
[TBL] [Abstract] [Full Text] [Related]
2. Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
Fonseca-Alves CE; Leis-Filho AF; Lacerda ZA; de Faria Lainetti P; Amorim RL; Rogatto SR
PLoS One; 2024; 19(4):e0297043. PubMed ID: 38564578
[TBL] [Abstract] [Full Text] [Related]
3. Oncocytoid Salivary Tumors: Differential Diagnosis and Utility of Newly Described Immunohistochemistry.
Katabi N
Head Neck Pathol; 2024 Mar; 18(1):20. PubMed ID: 38502259
[TBL] [Abstract] [Full Text] [Related]
4. Capivasertib: First Approval.
Shirley M
Drugs; 2024 Mar; 84(3):337-346. PubMed ID: 38388873
[TBL] [Abstract] [Full Text] [Related]
5. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Piha-Paul SA; Xu B; Dumbrava EE; Fu S; Karp DD; Meric-Bernstam F; Hong DS; Rodon JA; Tsimberidou AM; Raghav K; Ajani JA; Conley AP; Mott F; Fan Y; Fan J; Peng P; Wang H; Ni S; Sun C; Qiang X; Levin WJ; Ngo B; Ru QC; Wu F; Javle MM
Oncologist; 2024 Apr; 29(4):e514-e525. PubMed ID: 38297981
[TBL] [Abstract] [Full Text] [Related]
6. Tumor therapy by targeting extracellular hydroxyapatite using novel drugs: A paradigm shift.
Tantawy MN; McIntyre JO; Yull F; Calcutt MW; Koktysh DS; Wilson AJ; Zu Z; Nyman J; Rhoades J; Peterson TE; Colvin D; McCawley LJ; Rook JM; Fingleton B; Crispens MA; Alvarez RD; Gore JC
Cancer Med; 2024 Feb; 13(3):e6812. PubMed ID: 38239047
[TBL] [Abstract] [Full Text] [Related]
7. In vitro and in vivo pharmacokinetics, disposition, and drug-drug interaction potential of tinengotinib (TT-00420), a promising investigational drug for treatment of cholangiocarcinoma and other solid tumors.
Ni S; Li L; Sun X; Wang Y; Yu Q; Wang W; Gu Z; Yu Z; Wu D; Wu F; Jiang S; Peng P
Eur J Pharm Sci; 2024 Jan; 192():106658. PubMed ID: 38048851
[TBL] [Abstract] [Full Text] [Related]
8. Use of Drugs in Clinical Practice and the Associated Cost of cancer treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study.
Carreras MJ; Tomás-Guillén E; Farriols A; Renedo-Miró B; Valdivia C; Vidal J; Saura C; Carles J; Felip E; Gorgas MQ; Tabernero J; Monterde J
Curr Oncol; 2023 Aug; 30(9):7984-8004. PubMed ID: 37754495
[TBL] [Abstract] [Full Text] [Related]
9. Electrochemical aptasensor based on the engineered core-shell MOF nanostructures for the detection of tumor antigens.
Khan S; Cho WC; Sepahvand A; Haji Hosseinali S; Hussain A; Nejadi Babadaei MM; Sharifi M; Falahati M; Jaragh-Alhadad LA; Ten Hagen TLM; Li X
J Nanobiotechnology; 2023 Apr; 21(1):136. PubMed ID: 37101280
[TBL] [Abstract] [Full Text] [Related]
10. Frequencies of an Immunogenic her-2/
Goulielmaki M; Stokidis S; Anagnostou T; Voutsas IF; Gritzapis AD; Baxevanis CN; Fortis SP
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983028
[TBL] [Abstract] [Full Text] [Related]
11. Role of Ganetespib, an HSP90 Inhibitor, in cancer Therapy: From Molecular Mechanisms to Clinical Practice.
Youssef ME; Cavalu S; Hasan AM; Yahya G; Abd-Eldayem MA; Saber S
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902446
[TBL] [Abstract] [Full Text] [Related]
12. The Role of Theragnostics in Breast cancer: A Systematic Review of the Last 12 Years.
Balma M; Liberini V; Buschiazzo A; Racca M; Rizzo A; Nicolotti DG; Laudicella R; Quartuccio N; Longo M; Perlo G; Terreno E; Abgral R; William Huellner M; Papaleo A; Deandreis D
Curr Med Imaging; 2023; 19(8):817-831. PubMed ID: 36797602
[TBL] [Abstract] [Full Text] [Related]
13. Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer.
Franks J; Caston NE; Elkhanany A; Gerke T; Azuero A; Rocque GB
Breast Cancer Res Treat; 2023 Feb; 197(3):673-681. PubMed ID: 36539670
[TBL] [Abstract] [Full Text] [Related]
14. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
Yap TA; Bardia A; Dvorkin M; Galsky MD; Beck JT; Wise DR; Karyakin O; Rubovszky G; Kislov N; Rohrberg K; Joy AA; Telli ML; Schram AM; Conte U; Chappey C; Stewart R; Stypinski D; Michelon E; Cesari R; Konstantinopoulos PA
JAMA Oncol; 2023 Jan; 9(1):40-50. PubMed ID: 36394849
[TBL] [Abstract] [Full Text] [Related]
15. Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in cancer Therapy.
Gales L; Forsea L; Mitrea D; Stefanica I; Stanculescu I; Mitrica R; Georgescu M; Trifanescu O; Anghel R; Serbanescu L
Medicina (Kaunas); 2022 Sep; 58(9):. PubMed ID: 36143915
[TBL] [Abstract] [Full Text] [Related]
16. Association of HSD3B1 Genotype and Clinical Outcomes in Postmenopausal Estrogen-Receptor-Positive Breast cancer.
Flanagan MR; Doody DR; Voutsinas J; Wu Q; Banda K; Sharifi N; Li CI; Gadi VK
Ann Surg Oncol; 2022 Oct; 29(11):7194-7201. PubMed ID: 35776258
[TBL] [Abstract] [Full Text] [Related]
17. "PFH/AGM-CBA/HSV-TK/LIPOSOME-Affibody": Novel Targeted Nano Ultrasound Contrast Agents for Ultrasound Imaging and Inhibited the Growth of erbb2-Overexpressing Gastric cancer Cells.
Zhou H; Liu H; Zhang Y; Xin Y; Huang C; Li M; Zhao X; Ding P; Liu Z
Drug Des Devel Ther; 2022; 16():1515-1530. PubMed ID: 35611358
[TBL] [Abstract] [Full Text] [Related]
18. Marsdenia tenacissima (Roxb.) Moon injection exerts a potential anti-tumor effect in prostate cancer through inhibiting erbb2-GSK3β-HIF1α signaling axis.
Chen X; Luo Z; Liu X; Li X; Li Q; Zhang W; Liu Y; Cheng Z; Yang X; Liu Y; Jin R; Zhu D; Wang F; Lu Q; Su Z; Guo H
J Ethnopharmacol; 2022 Sep; 295():115381. PubMed ID: 35595220
[TBL] [Abstract] [Full Text] [Related]
19. The relationship between her2 expression and
Ozen A; Tatar G
Hell J Nucl Med; 2022; 25(1):5-10. PubMed ID: 35388798
[TBL] [Abstract] [Full Text] [Related]
20. Enhanced antitumor efficacy by combining afatinib with MDV3100 in castration-resistant prostate cancer.
Li J; Wu H; Lv S; Quan D; Yang D; Xu J; Chen B; Ou B; Wu S; Wei Q
Pharmazie; 2022 Feb; 77(2):59-66. PubMed ID: 35209965
[No Abstract] [Full Text] [Related]
[Next]
